



Copenhagen, 28 February 2003

**PRESS RELEASE**

*FOR IMMEDIATE RELEASE*

**US Patent Granted for Method to Detect Protein Translocations in Cells -  
Redistribution™**

BioImage A/S today announced that it had been granted US 6,518,021, a patent covering the detection of protein translocation in cells using luminophores, such as green fluorescent protein (GFP), fused to the target protein. Redistribution™ - the name coined by the company to describe its technology that monitors protein translocation in real time in living cells - is at the heart of the company's drug discovery programs. BioImage has pioneered the concept of modulating protein translocation as a new mode of action for disease therapy.

Dr. Patrik Dahlén, CEO of BioImage, said, "This patent extends our IP portfolio in the US and further strengthens our internal discovery programs and external partnerships. It also recognizes BioImage's leadership in an exciting growth area - high throughput, high content screening of living cells. Every pharmaceutical and drug discovery company exploring protein translocation assays will need access to our technology and IP. We look forward to continuing our own in-house discovery programs and to working with a growing number of strategic commercial partners. High content screening is an increasingly interesting area in which technologies and assays, such as those developed by BioImage, provide researchers with cost effective methods for characterizing lead compounds in more relevant, cell-based assays. Our ability to run these assays in high throughput mode also allows us to run them routinely as primary screens."

Using Redistribution, BioImage has screened for and identified small drug-like molecules that act as modulators of protein translocation. These drug-like molecules work through new modes of action and show early promise as therapies in inflammation and cancer. The company plans to progress these compounds through lead optimization and *in vivo* studies later in the year. In addition to using Redistribution for its own in-house discovery programs, the Company believes that the technology will be more broadly used as a vital drug discovery tool. In particular, the technology is applicable to pathway screening, where specific intracellular signaling pathways are screened for small molecule interactors upstream from the target in the process of profiling lead compounds. Through its technology access partnerships, BioImage is looking for further licensees to ensure access to the technology and has already made its Redistribution technology available under license to companies in the biotech and pharmaceutical industry.

**Contacts:**

Ulrik Vejlsgaard, Chief Operating Officer, BioImage A/S, Moerkhoej Bygade 28, DK-2860 Soeborg, Denmark

Tel: +45 44 43 34 44 Fax: +45 44 43 75 05

E-mail: [ulrik.vejlsgaard@bioimage.com](mailto:ulrik.vejlsgaard@bioimage.com) Web: [www.bioimage.com](http://www.bioimage.com)

Peter Colley, Northbank Communications Ltd., Meadowside, Mountbatten Way, Congleton, CW12 1DN, UK

Tel: +44 (0) 1260 296500 Fax: +44 (0) 1260 296501

E-mail: [p.colley@northbankcommunications.com](mailto:p.colley@northbankcommunications.com) Web: [www.northbankcommunications.com](http://www.northbankcommunications.com)

**Notes for Editors:**

BioImage A/S uses its expertise in redistribution™ technologies to discover drug candidates that change the activity of specific signaling pathways without inhibiting the catalytic activity of signaling proteins. In response to stimuli such as drugs, the intracellular location of these proteins may change. These translocations involve specific interactions that are known to be critical steps in signaling pathways. Increased or decreased activity of a pathway is achieved by targeting these exquisitely specific interactions by which signaling proteins control cellular information flow. BioImage specializes in discovering leads against known signaling targets that cannot be inhibited with absolute specificity by traditional means. The company's high-throughput, high content cell-based redistribution assays make these targets amenable to drug discovery. Some of these assays have been made available from Amersham Biosciences through a collaborative agreement with BioImage.

Drugs discovered using BioImage's technology should operate through a new mode of action that will demonstrate completely different selectivity profiles compared to traditional active-site inhibitors and are likely to produce fewer side effects. The company's novel approach offers exceptional target and drug discovery opportunities in most therapeutic areas. BioImage has active projects in the areas of cancer and inflammatory and autoimmune diseases and will commercialize drug candidates discovered in these programs through collaborations with pharmaceutical and biotechnology companies. Presently the company works with Lexicon Genetics to discover such protein translocation modulators.

BioImage employs approximately 50 people at its research facility in Copenhagen, at the center of Medicon Valley. The company is financially backed by leading international investors including Apax Partners, Abingworth Management Ltd. and Novo A/S.

For more information please visit [www.bioimage.com](http://www.bioimage.com)